PMID- 7511533
OWN - NLM
STAT- MEDLINE
DCOM- 19940503
LR  - 20190825
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 23
IP  - 12
DP  - 1993 Dec
TI  - House dust mite allergy: from T-cell epitopes to immunotherapy.
PG  - 763-72
AB  - CD4+ T-lymphocytes induce and regulate allergic inflammatory responses to common 
      environmental aeroallergens derived from Dermatophagoides spp. (house dust mite, 
      HDM), which cause clinical symptoms in approximately 10% of the population. 
      Definition of the molecular structure of HDM proteins combined with the ability 
      to isolate monoclonal populations of human CD4+ T-cells representative of the 
      'interleukin-4 (IL-4) dominant' functional phenotype, which support 
      immunoglobulin E (IgE) synthesis, has allowed T-cell recognition of HDM to be 
      examined in detail. The results of these investigations demonstrated extensive 
      heterogeneity in both the antigen and HLA class II restriction specificity of the 
      HDM reactive T-cell repertoire. Furthermore, long-lived clones of T-cells with 
      oligoclonality in T-cell antigen receptor (TcR) usage, driven by chronic 
      stimulation with HDM, have been identified in human peripheral blood. The 
      presentation of specific peptides and superantigens under conditions that induce 
      T-cell non-responsiveness has provided an in vitro model for analysing the 
      mechanisms of CD4+ T-cell targeted immunotherapy. It appears that the mechanisms 
      underlying T-cell anergy are accompanied by a transient downregulation of TcR and 
      CD28 and mediated by a shift in the cytokine profile from that of the 'IL-4 
      dominant' to the 'interferon-gamma (IFN-gamma) dominant' functional phenotype of 
      CD4+ T-cells. In parallel, using a murine model, it has been demonstrated that 
      administration of an immunodominant peptide via the mucosal surfaces of the 
      respiratory and alimentary tracts may tolerize an established response to intact 
      HDM proteins. The potential application of these models in the development of 
      novel approaches to immunotherapy is discussed.
FAU - O'Hehir, R E
AU  - O'Hehir RE
AD  - Department of Immunology, St. Mary's Hospital Medical School, Imperial College of 
      Science, Technology and Medicine, London.
FAU - Hoyne, G F
AU  - Hoyne GF
FAU - Thomas, W R
AU  - Thomas WR
FAU - Lamb, J R
AU  - Lamb JR
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Allergens)
RN  - 0 (Dust)
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Allergens/chemistry/immunology
MH  - Animals
MH  - Dust/*adverse effects
MH  - Epitopes/chemistry/immunology
MH  - Histocompatibility Antigens Class II/immunology
MH  - Humans
MH  - Hypersensitivity/*therapy
MH  - Immunotherapy
MH  - Mites/*immunology
MH  - T-Lymphocytes/*immunology
RF  - 62
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2362.1993.tb00729.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1993 Dec;23(12):763-72. doi: 
      10.1111/j.1365-2362.1993.tb00729.x.